Cipher Pharmaceuticals (TSE:CPH) Announces Earnings Results

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) released its earnings results on Tuesday. The company reported C$0.21 earnings per share for the quarter, FiscalAI reports. Cipher Pharmaceuticals had a return on equity of 25.69% and a net margin of 60.82%.The company had revenue of C$17.14 million for the quarter.

Cipher Pharmaceuticals Price Performance

TSE:CPH opened at C$17.95 on Wednesday. The business’s 50-day simple moving average is C$16.68 and its two-hundred day simple moving average is C$16.61. Cipher Pharmaceuticals has a 52 week low of C$12.48 and a 52 week high of C$20.56. The stock has a market cap of C$455.77 million, a PE ratio of 15.08 and a beta of 1.15. The company has a quick ratio of 2.67, a current ratio of 1.25 and a debt-to-equity ratio of 0.32.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group set a C$17.00 price objective on Cipher Pharmaceuticals and gave the stock a “hold” rating in a research note on Tuesday, May 12th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of C$17.00.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.